<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Loss of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene function can occur as a result of epigenetic silencing of large chromosomal regions, referred to as long-range epigenetic silencing (LRES), and genome-wide analyses have revealed that LRES is present in many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types </plain></SENT>
<SENT sid="1" pm="."><plain>Here we utilize Illumina Beadchip methylation array analysis to identify LRES across 800â€‰kb of chromosome 5q31 in colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:mp ids='MP_0002038'>carcinomas</z:mp> (n=34) relative to <z:mpath ids='MPATH_458'>normal</z:mpath> colonic epithelial DNA (n=6) </plain></SENT>
<SENT sid="2" pm="."><plain>This region encompasses 53 individual protocadherin (PCDH) genes divided among three gene clusters </plain></SENT>
<SENT sid="3" pm="."><plain>Hypermethylation within these gene clusters is asynchronous; while most PCDH hypermethylation occurs early, and is apparent in <z:mpath ids='MPATH_270'>adenomas</z:mpath>, PCDHGC3 promoter methylation occurs later in the <z:mpath ids='MPATH_270'>adenoma</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> transition </plain></SENT>
<SENT sid="4" pm="."><plain>PCDHGC3 was hypermethylated in 17/28 <z:mp ids='MP_0002038'>carcinomas</z:mp> (60.7%) according to methylation array analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Quantitative real-time reverse transcription-polymerase chain reaction showed that PCDHGC3 is the highest expressed PCDH in <z:mpath ids='MPATH_458'>normal</z:mpath> colonic epithelium, and that there was a strong reciprocal relationship between PCDHGC3 methylation and expression in <z:mp ids='MP_0002038'>carcinomas</z:mp> (R=-0.84) </plain></SENT>
<SENT sid="6" pm="."><plain>PCDH LRES patterns are reflected in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumour</z:e> cell lines; <z:mpath ids='MPATH_270'>adenoma</z:mpath> cell lines are not methylated at PCDHGC3 and show abundant expression at the <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein level, while the expression is suppressed in hypermethylated <z:mp ids='MP_0002038'>carcinoma</z:mp> cell lines (R=-0.73) </plain></SENT>
<SENT sid="7" pm="."><plain>Short-interfering <z:chebi fb="40" ids="33697">RNA</z:chebi>-mediated reduction of PCDHGC3 led to a decrease of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in RG/C2 <z:mpath ids='MPATH_270'>adenoma</z:mpath> cells, and overexpression of PCDHGC3 in HCT116 cells resulted in the reduction of colony formation, consistent with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor capabilities for PCDHGC3 </plain></SENT>
<SENT sid="8" pm="."><plain>Further functional analysis showed that PCDHGC3 can suppress Wnt and mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> signalling in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, our data suggest that the PCDH LRES is an important <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor locus in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and that PCDHGC3 may be a strong marker and driver for the <z:mpath ids='MPATH_270'>adenoma</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> transition </plain></SENT>
</text></document>